Fatal Trichosporon asahii septicemia in a Guatemalan farmer with acute lymphoblastic leukemia [3]

Southern Medical Journal

Volumn 98, Issue 9, 2005, Pages 954-955

  Chan Tack, Kirk M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; FLUCONAZOLE; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN; VORICONAZOLE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGRICULTURAL WORKER; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER PATIENT; CASE REPORT; CAUSE OF DEATH; FUNGUS CULTURE; GUATEMALA; HUMAN; LETTER; MALE; MULTIPLE ORGAN FAILURE; MYCOSIS; NEUTROPENIA; RESPIRATORY FAILURE; SEPTICEMIA; TREATMENT OUTCOME; TRICHOSPORON ASAHII; TRICHOSPORONOSIS;

ADULT; AGRICULTURE; ANTIFUNGAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CATHETERIZATION, PERIPHERAL; EMIGRATION AND IMMIGRATION; FATAL OUTCOME; FEVER; GUATEMALA; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; MYCOSES; NEUTROPENIA; PYRIMIDINES; SEPSIS; TRIAZOLES; TRICHOSPORON; UNITED STATES; UREASE; YEASTS;

EID: 25844456839     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.smj.0000177350.91609.ea     Document Type: Letter

References (22)

1. Gueho E, Improvisi L, de Hoog GS, et al. Trichosporon on humans: a practical account. Mycoses 1994;37:3-10.
2. Haupt HM, Merz WG, Beschomer WE. Colonization and infection with Trichosporon species in the immunosuppressed host. J Infect Dis 1983;147:199-203.
3. Walsh TJ, Newman KR, Moody M, et al. Trichosporonosis in patients with neoplastic disease. Medicine (Baltimore) 1986;65:268-279.
4. Walsh TJ, Melcher GP, Lee JW, et al. Infections due to Trichosporon species: new concepts in mycology, pathogenesis, diagnosis and treatment. Curr Top Med Mycol 1993;5: 79-113.
5. Walsh TJ, Groll A, Hiemenz J, et al. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 2004;10 (suppl 1):S48-S66.
6. Itoh T, Hosokawa H, Kohdera U, et al. Disseminated infection with Trichosporon asahii. Mycoses 1996;39:195-199.
7. Leaf HL, Simberkoff MS. Invasive Trichosporonosis in a patient with acquired immunodeficiency syndrome. J Infect Dis 1989; 160:356-357.
8. Mirza SH. Disseminated Trichosporon beigelii infection causing skin lesions in a renal transplant patient. J Infect 1993;27:67-70.
9. Hajjeh RA, Blumberg HM. Bloodstream infection due to Trichosporon beigelii in a burn patient: Case report and review of therapy. Clin Infect Dis 1995;20:913-916.
10. Finkelstein R, Singer P, Lefler E. Catheter-related fungemia caused by Trichosporon beigelii in non-neutropenic patients. Am J Med 1989;86:133.
11. Vasta S, Menozzi M, Scime R, et al. Central catheter infection by Trichosporon beigelii after autologous blood stem cell transplantation. A case report and review of the literature. Haematologica 1993;78:64-67.
12. Yuen KY, Seto WH, Li KS, et al. Trichosporon beigelii peritonitis in continuous ambulatory peritoneal dialysis. J Infect 1990; 20:178-180.
13. Martinez-Lacasa J, Mana J, Niubo R, et al. Long-term survival of a patient with prosthetic valve endocarditis due to Trichosporon beigelii. Eur J Clin Microbiol Infect Dis 1991;10:756-758.
14. Anaissie EJ, Hachem R, Karyotakis NC, et al. Comparative efficacies of amphotericin B, triazoles, and combination of both as experimental therapy for murine Trichosporonosis. Antimicrob Agents Chemother 1994;38:2541-2544.
15. Uzun O, Kocagöz S, Cetinkaya Y, et al. In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Antimicrob Agents Chemother 1997;41:1156-1157.
16. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998;36:2950-2956.
17. Anaissie E, Gokaslan A, Hachem R, et al. Azole therapy for Trichosporonosis: clinical evaluation of eight patients, experimental therapy for murine infection, and review. Clin Infect Dis 1992;15:781-787.
18. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 1998;36:198-202.
19. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, et al. In vitro antifungal susceptibilities of Trichosporon species. Antimicrob Agents Chemother 2002;46:1144-1146.
20. Falk R, Wolf DG, Shapiro M, et al. Multidrug-resistant Trichosporon asahii isolates are susceptible to voriconazole. J Clin Microbiol 2003;41:911.
21. Fournier S, Pavageau W, Feuillhade M, et al. Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia. Eur J Clin Microbiol infect Dis 2002;21:892-896.
22. Kontoyiannis DP, Torres HA, Chagua M, et al. Trichosporonosis in a tertiary care cancer center: risk factors, changing spectrum and determinants of outcome. Scand J Infect Dis 2004;36:564-569.